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Androgens/Female Clinical/Female Basic Science
Screening and monitoring in men prescribed
testosterone therapy in the U.S., 2001–2010.
J Baillargeon, RJ Urban, YF Kuo, HM Holmes,
MA Raji, A Morgentaler, BT Howrey, YL Lin, KJ
Ottenbacher. PublicHealth Rep 2015;130:143–52.
Editorial Comment: Testosterone therapy for
late-onset hypogonadism is a controversial prac-
tice. What is not controversial is the need for
appropriate patient selection and careful monitor-
ing for treatment emergency adverse events in
those patients who do choose to initiate testoster-
one therapy. While individual practitioners may
vary in the details of their follow-up protocols, all
experts agree that patients should be followed.
This follow-up must include physical examination
and routine laboratory testing.
This insurance claims database makes clear a
distressing reality; there exist a substantial number
of U.S. men being treated with testosterone
without proper testing before initiation of therapy
and/or absence of follow-up serum after therapy
has been initiated. As would be expected, clinicians
with particular expertise in hypogonadism were
more likely to adhere to established guidelines.
The issue of PSA screening is itself controver-
sial, and hence, some providers may opt to defer
this testing altogether. While deferral of PSA
testing may be appropriate in properly counseled
patients, it is counter-intuitive, and perhaps
medico-legally risky, to avoid PSA testing in a
patient receiving a therapy that has been associated
withPSAchanges andprostate cancer. Setting aside
the issue of PSA, it is clearly inappropriate not to
test serum testosterone level before starting treat-
ment and/or after therapy has been initiated.While
there is controversy about appropriate cutoff levels
for “low testosterone,” very few studies support any
beneﬁt from supplementation in men with total
serum testosterone levels greater than 400 ng/dL;
indeed, most studies recommend a much lower cut
point around 300 ng/dL. Supplementing men who
may have serum levels greater than these cutoffs is
potentially risky and of unclear clinical beneﬁt.
Unfortunately, providers who are not knowl-
edgeable about established cut-offs are likely less
prone to read literature such as this paper. It
behooves medical practices and regulatory agen-
cies to ensure that their practitioners adhere to the
best available evidence-based guidelines; at a
minimum, this should mean pretreatment assess-
ment of serum testosterone levels and follow-up to
ensure appropriate supplementation is achieved.
Alan W. Shindel, MD, MAS
Hypogonadal symptoms are associated with
different serum testosterone thresholds in
middle-aged and elderly men. R Ramasamy,
N Wilken, JM Scovell, JR Kovac, LI Lipshultz.
Urology 2014;84:1378–82.
Editorial Comment: There exists substantial
controversy about serum testosterone levels; what
constitutes “low T”? Reference ranges vary widely
between labs, and assays themselves are prone to
marked variation. Aside from issues with testoster-
one itself, there is a growing body of evidence to
suggest that variations in the androgen receptor
may modulate the potency of serum testosterone
in vivo. When coupled with the generally vague
nature of “low T” symptoms, proper patient selec-
tion can be challenging.
Most organizations to date have favored a cutoff
range around 300 ng/dL serum testosterone for
“low testosterone.” This interesting study suggests
that a “one-size-ﬁts-all” approach to serum testos-
terone testing may not be appropriate and that
some men with higher testosterone levels may still
have signiﬁcant symptom burden. Interestingly,
decreased libido, one of the more common low T
complaints, became increasingly prevalent in men
with serum levels less than 375 ng/dL, well above
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the more standard cut off of 300 ng/dL. Progres-
sively lower levels (still over 300 ng/dL) corre-
sponded with increasing prevalence of the physical
symptoms of low testosterone (decreased ability
with sports, loss of strength, etc). Wu et al. [1]
reported that certain symptoms of testosterone
deﬁciency become more prevalent with progres-
sively lower serum levels, so this paper adds to this
prior work.
The study is limited in its use of the nonspeciﬁc
ADAM questionnaire. It does however give cre-
dence to the notion that clinicians should use their
own judgment and carefully counsel patients who
have symptoms of low T and borderline levels.
Supplementation may be of beneﬁt in such men,
but careful discussion and informed consent of the
patient are essential.
Alan W. Shindel, MD, MAS
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Female Clinical Science
Mechanism of action of Fibanserin, a multi-
functional serotonin agonist and antagonist
(MSAA), in hypoactive sexual desire disorder.
SM Stahl. CNS Spectr 2015;20:1–6.
Editorial Comment: For decades, the ﬁeld of
sexual medicine has been bombarded by scientiﬁc
breakthroughs when it comes to pathophysiolo-
gical understanding of the endocrinological aspects
of male sexual function and dysfunction. We have
noticed a signiﬁcant lag in the understanding when
it pertains to female sexual health and wellness.
This article takes a deep dive into the female brain
and hormonal regulation of female sexual interest
and desire. We now can glean from the presented
evidences that sexual desire is regulated not only by
sex hormones (e.g., testosterone, estrogen, and
progesterone) but also by brain neurotransmitters.
Principle among these are dopamine and norepi-
nephrine, which work in concert to enhance sexual
interest and desire. Serotonin levels are also critical
as they appear to act directly to inhibit sexual inter-
est and desire.
Brain circuitry involved in connecting the
prefrontal cortex with emotional/limbic pleasure
centers may be integrally involved in mediating
personal and sexual motivation, interest, and
desire. One may consider that dysregulation in
these circuits will result in abnormal and/or deﬁ-
cient information processing; this may result in
disorders of sexual interest and desire. Flibanserin,
a novel medication which has recently been resub-
mitted to the Food and Drug administration for
approval for female HSDD, is a multifunctional
serotonergic agent with both 1A agonist and a
serotonin 2A antagonist properties.
Flibanserin’s most likely mechanism of action is
by boosting pathways involved in the release of
dopamine and norepinephrine while concurrently
reducing serotonin release. By these mechanisms,
the drug facilitates an improvement in sexual func-
tioning with associated decrease in sex-related
distress. Flibanserin is a novel multifunctional
serotonin agonist and antagonist that has demon-
strated improved sexual functioning in premeno-
pausal women who suffer from reduced sexual
interest and desire. This review is a must read!
Michael Krychman, MD
Bariatric surgery: Impact on sexuality of the
obese personCirurgia bariátrica: Repercussões
na sexualidade da pessoa obesa. ML Lobato
Mariano,MA Boccaro de Paula, DGermano Bassi,
PRoberto dePaula. RevCol BrasCir 2014;41:412–
20.
Editorial Comment: Obesity is running rampant
both globally and within the United States. We
have long recognized some of the medical and
physical ramiﬁcations from increased body mass
index (BMI) and have now labeled obesity a
medical illness which warrants intervention to
decrease morbidity and mortality. Obesity is con-
sidered grade I when the BMI is less than 30 kg/
m2, grade II when the BMI is equal to or greater
than 35 kg/m2, and grade III when the BMI is
equal to or greater than 40 kg/m2. Sexual problems
and dysfunction have long been associated with
changes in weight, and it has been demonstrated
that severe obesity is a contributing facet to poor
overall sexual functioning.
Many patients are now opting for aggressive
surgical treatment for obesity. While treatment is
effective in managing weight issues, there are
limited data on sexual function outcomes in these
patients. Increased attention to postoperative
sexuality issues is an important component of
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overall quality of life assessment in patients who
have undergone bariatric surgery.
Obese people may experience a variety of
medical and psychological ramiﬁcations from their
increased weight including (but not limited to)
discrimination, body image disorders, anxiety,
depression, low self-esteem, isolation, hyperten-
sion, metabolic syndrome, and diabetes. Morbid
obesity may directly impact sexuality by fatigue,
decreased physical stamina/mobility, lower sexual
self-esteem, and/or guilt and shame. There are
positive outcomes of physical and emotional
domains after the surgical treatment of obesity,
favoring the improved quality of life, including
sexuality.
This small yet signiﬁcant qualitative/
quantitative research study followed a nonrandom
sample of 30 patients who had undergone Fobi-
Capella Roux-Y gastric bypass. Data collection
occurred through individual interviews and ques-
tionnaires between May and June 2011. The mean
age of the patients was 44 ± 12 years. The majority
of participants (24, 80%) were female. Seventy-
seven percent were married. Almost all (96%) had
hypertension, whereas only and eight (33%) had
diabetes. The average weight loss postoperatively
was 44 ± 13.8 kg for women and 47 ± 16.3 kg for
men. Mean weight loss as a percentage was 36%
for both genders.
Postoperatively, 63% of participants reported
that sexual frequency was changed: 16 (53%)
reported increased sex frequency, one (3%)
reported a decrease in frequency, one (3%) com-
pletely stopped having intercourse, and one (3%)
did not report on sex frequency; 37% of individu-
als reported no change in intercourse frequency.
Data such as these support the notion that
sexual health improves with management of
obesity. As the population ages, and as obesity and
morbid obesity become more prevalent, it is criti-
cal for us to examine our own preconceived
notions on obesity and recognize that bariatric
surgery may provide a new start toward improved
sexual function, desire, and sexual capacity.
Michael Krychman, MD
The use of magnetic resonance imaging for
studying female sexual function: A review. CM
Vaccaro. Clin Anat 2015;28:324–30.
Editorial Comment: With recent advances in the
peripheral neurological and endocrine under-
standing of female sexual functioning, a logical
next step is further investigation of the sexual
organs and brain via advanced imaging technology.
Noninvasive magnetic resonance imaging (MRI) is
useful in sex research in order to better discern the
underlying mechanisms of female sexual health.
MRI is more sensitive than ultrasound and
computed tomography for examining small differ-
ences in tissue properties. This capability has made
MRI useful in investigation of both mental and
physical factors involved in female sexual function.
For instance, Arnow et al. demonstrated differen-
tial brain activation and deactivation in those with
hypoactive sexual desire disorder and those
without this disorder [1]. Functional MRI (fMRI)
has also been used in the clinical setting to reveal
central sexual excitation. FMRI is able to detect
even slight changes in blood ﬂow; this property
has enabled the discovery that with normative
sexual response, there is deactivation of the frontal
lobe and activation of the instinctual limbic system
of the midbrain.
MRI has also been instrumental in assessment
and documentation of the complete clitoral
complex. Careful imaging studies have demon-
strated the distinct nature of the clitoral glans and
the paired clitoral corpora, crura, and bulbs.
Important discoveries have included documenta-
tion of the average clitoral sizes and its associated
structures as well as the distances between the cli-
toral complex and other pelvic structures.
Interestingly, MRI-based anatomical measure-
ments have been associated with variation in
female sexual function. For instance, increased dis-
tance between the clitoral complex and the vaginal
lumen correlates with poorer sexual function.
Genital and subjective arousal are only weakly cor-
related in women; however, physiological engorge-
ment is beneﬁcial for many aspects of female sexual
arousal. Indeed, it is the opinion of many sexual
medicine specialists that arousal disorder is likely
to due to a combination of inadequate desire, deﬁ-
cient central activation, and poor peripheral vascu-
lar engorgement.
Unfortunately, MRI is expensive in the US (less
so in other countries), lacks portability, is both
time-consuming, and may be difﬁcult in patients
who are claustrophobic or sensitive to noise. Fur-
thermore, MRI is contraindicated in patients with
metal implants. Despite these limitations, MRI
technology is an increasingly vital adjunct in clini-
cal research for female sexuality. It is conceivable
that in the near future, MRI may have direct clini-
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cal applications in the diagnosis and management
of female sexual concerns.
Michael Krychman, MD
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Female Mental Health
Sensual, erotic, and sexual behaviors of women
from the “kink” community. JE Rehor. Arch Sex
Behav 2015;44:825–36.
Editorial Comment: Individuals who engage in
unconventional sensual, erotic, and sexual behav-
iors (sometimes referred to as “kink”) have rou-
tinely been understudied. Women who engage in
these behaviors have been particularly marginal-
ized, with previous studies on kink behavior
focused on clinical or criminal samples. There is a
dearth of information regarding women who con-
sensually engage in kink behaviors and what types
of behaviors they engage in.
In this study, a nonclinical/noncriminal sample
of 1,580 female participantswere recruited through
kink community events and online forums. Partici-
pants were invited to ﬁll out an online question-
naire asking about the types of kink activities these
women have participated in and the type of partici-
pation (doing to, having done to, observing). The
questionnaire asked about 126 sensual, erotic, and
sexual behaviors among these women including 62
BDSM-related behaviors, 10 role-play scenarios,
ﬁve forms of exhibitionistic behaviors, eight forms
of erotica, ﬁve broad categories of fetishistic behav-
iors, 24 overt sexual activities, and 12miscellaneous
erotic activities.
The researchers determined that women in the
kink community willingly engage in a much wider
variety of erotic activities than has previously been
documented in the literature. Of interest, 85%
percent of the sample indicated using bondage
toys, 82% indicated that they have observed some
type of erotica, and 56% indicated engaging in
some type of exhibitionistic activity (e.g., showing
bare breasts, engaging in public sex, posing or
sharing images, etc.) for their own sensual or erotic
pleasure.
The results of this study provide educators,
counselors, therapists, and medical professionals a
much better understanding of the depth and
breadth of activities women willingly engage in the
kink community. It also adds to the literature by
providing data on kink behaviors in women from a
nonpathologizing perspective.
Rose Hartzell-Cushanick, PhD, EdS, CHES, LMFT
Women’s motivations to have sex in casual and
committed relationships with male and female
partner. HL Armstrong, ED Reissing. Arch Sex
Behav 2015;44:921–34.
Editorial Comment: Women are motivated to
engage in sexual activity for a variety of reasons, and
these motivations may change from one context to
another. A better understanding of how these
sexual motives work in women can help sex thera-
pists, educators, and physicians more effectively
work with women with low sexual desire or those
engaging in risky sexual behavior.
In this study, the authors explored how relation-
ship type, sexual attraction, and the gender of
one’s partner interact and affect sexual motivation.
Women were recruited at a large university
through online advertising and by word-of-mouth.
A total of 510 women completed the YSEX?
Questionnaire. This survey posed questions about
motivations for sex in the past and/or what would
motivate them to engage in sexual activity in the
future. Examples of potential enticements to sex
included wanting to achieve an orgasm, being
“horny,” and/or the potential partner’s physical
appearance “turning them on.”
The authors report that the type of relationship
(casual vs. committed) affected the women’s
reportedmotivation for sex. For causal sex, physical
reasons were most frequently endorsed as motiva-
tions, whereas for committed relationships, women
more frequently motivated by emotional needs/
desires. These results were consistent regardless of
the gender of their partner (i.e., if their potential
partner was another woman or a man).
This study is an important contribution to
the literature and can beneﬁt sexual health
practitioners/therapists working with women by
providing them with more insight into women’s
sexual motivations (e.g., in working with women
reporting symptoms of low sexual desire). In addi-
tion, the similarity in sexual motivation for
women, regardless of sexual orientation or gender
of partner, is also noteworthy.
Rose Hartzell-Cushanick, PhD, EdS, CHES, LMFT
58 Sex Med 2015;3:55–61
Sexual Pain
Prevalence of symptoms consistent with a
diagnosis of vulvodynia: Population-based
estimates from 2 geographic regions. BL
Harlow, CG Kunitz, RH Nguyen, SA Rydell,
RM Turner, RF MacLehose. Am J Obstet
Gynecol 2014;210:40.e1–8. doi:10.1016/j.ajog
.2013.09.033.
Editorial Comment: Vulvodynia, or idiopathic
vulvar pain, is a frequent cause of sexual pain, now
classiﬁed as genito-pelvic pain in the DSM-5 [1].
Vulvodynia adversely impacts women’s sexual
health, psychological well-being, and quality of
life. Unfortunately, most studies in the area, both
biomedical and psychosocial, are characterized by
relatively small clinical samples. This signiﬁcant
limitation introduces a selection bias associated
with clinically referred participants, who typically
show higher levels of symptomatology. The ﬁeld is
in dire need of large-scale community-based
studies; such data will inform scientists and health
care providers about population prevalence, help-
seeking behaviors and attitudes, and risk factors
for the development of this neglected women’s
sexual health issue.
One such important study was recently pub-
lished [2]. Bernard Harlow and his team gathered
epidemiologic data from 5,440 premenopausal
women from three ethnically diverse neighbor-
hoods and two west suburban communities of the
Boston metropolitan area (BMA) between 2001
and 2005, and 13,681 from all geographic loca-
tions within the Minneapolis/St Paul metropoli-
tan area (MSP) between 2010 and 2012.
Participants completed the self-report measures
concerning their history of vulvar pain that inter-
fered with vaginal intercourse and that lasted
more than 3 months. Participants from BMA
were systematically sampled from census-based
directories, and those from MSP stemmed from
an administrative database of women who were
seen for any reason at one of several outpatient
community clinics within that deﬁned geographic
region.
Although boasting large representative
samples, community-based studies have the inevi-
table disadvantage of needing to forego more
in-depth assessment of study participants. In the
case of vulvodynia, this may mean that women
cannot take part in a gynecological examination
to conﬁrm their diagnosis. To circumvent this
caveat, Harlow and colleagues ﬁrst developed a
vulvar pain questionnaire which has shown 83%
sensitivity and 94% speciﬁcity for meeting a
medical diagnosis of vulvodynia, based on the
cotton swab test and other elements of clinical
examination to rule out potential known causes
of vulvar pain [3].
To determine age-speciﬁc cumulative inci-
dence in the present study, the authors deﬁned
vulvodynia as pain on contact in the last 6
months that limited or prevented intercourse.
Results indicate that for both samples, the rate of
ﬁrst onset of vulvodynia was highest prior to the
age of 25 years, decreased during the late 20s and
early 30s, and then increased in participants’ late
30s. These results are similar to what is often
observed clinically when speaking to women with
sexual pain. Interestingly, women of Hispanic
ethnicity were at an increased risk of developing
vulvodynia.
Overall, 7–8% of women in this study reported
symptoms consistent with vulvodynia by age 40.
Among women with vulvodynia, between 30% and
48% never sought treatment; unfortunately, over
50% of those who sought care never received a
diagnosis. Those with primary vulvodynia (i.e.,
pain on genital contact/intercourse since the ﬁrst
vaginal intercourse attempt) were more likely to
have sought treatment compared with women with
secondary vulvodynia (i.e., pain after a period of
pain-free intercourse).
Two signiﬁcant conclusions can be drawn from
this study. First, vulvodynia is a highly prevalent
condition that is often neglected by many health
care professionals. Potential explanations for
failure to address the issue in practice include
ignorance, lack of training, discomfort discussing
sexuality, and feelings of helplessness in the face
of a persistent yet private pain condition that is
challenging to treat. Second, almost half of
women with vulvodynia do not seek treatment;
even those women who do seek treatment are
frequently frustrated by failure to receive a diag-
nosis. One may glean from this that existing
studies on vulvodynia based on clinical samples
represent a self-selected, limited, and biased
group of women. Given that the best available
data may be based on a biased population, it may
be inferred that accurate knowledge on
vulvodynia is less than accurate, even among
sexual medicine specialists.
Sophie Bergeron, PhD
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Basic Science
Impact of prolapse meshes on the metabolism
of vaginal extracellular matrix in rhesus
macaque. R Liang, W Zong, S Palcsey, S
Abramowitch, PA Moalli. Am J Obstet Gynecol
2015;212:174e1–e7.
Editorial Comment: Surgery for pelvic organ
prolapse has increased since 2004 when the FDA
approved the ﬁrst mesh kits required to aid
insertion of synthetic vaginal grafts during recon-
struction. As a consequence, the use of the polypro-
pylene mesh has improved surgical outcomes;
however, mesh-related complications, such as pain,
infection, and erosion may still occur. As a result,
the FDA has issued public health notiﬁcations
warning of complications related to mesh used for
prolapse surgery and requested that additional
research be conducted. Preclinical studies examin-
ing themechanisms and outcomes of vaginal recon-
struction are limited, as are comparisons between
various mesh properties. In vivo studies are
required to evaluate various types of mesh as their
properties change in situ.
In this study, Liang et al. evaluated collagen and
elastin metabolism after implantation of meshes
that varied inweight, stiffness, and porosity. Rhesus
macaques were divided into ﬁve groups in which
hysterectomy was performed and each group
was implanted with one of the following mesh
types: Gynemesh PS®; UltraPro Perpendicular®;
UltraPro Parallel®; or Restorelle®. A control
group received no mesh. Twelve weeks later, tissue
was harvested for analysis.Western blot techniques
were used to measure precursors, degradation
enzymes and products of collagen and elastin.
While subtle differences in the various materials
were detected, implantation with heavier, stiffer,
and/or less porous mesh (e.g. Gynemesh PS), was
associated with increased catabolism of collagen
and elastin in the vagina, increased matrix degrada-
tion, and an increase in matrix metalloproteinase
(MMPs) enzymes (interstitial collagenase and
ﬁbroblast collagenase). The lighter, more porous,
and less stiff meshes (e.g. UltraPro® and
Restorelle®) had less of a negative impact on the
remodeling of the elastin and collagen in the
vagina.
The authors propose that further studies on the
mechanisms by which the body activates MMPs in
response to various mesh properties might help
provide superior materials with less adverse
effects.
Lesley Marson, PhD
Paced mating behavior is affected by clitoral–
vaginocervical lidocaine application in combi-
nation with sexual experience. SH Meerts,
HK Strnad, RS Schairer. Physiol & Behav
2015;140:222–9.
Editorial Comment: Rodents are the primary
species used to study sexual behavior.
Genitosensory information received during sexual
behavior modulates the intensity of subsequent
lordosis responsiveness, proceptive behavior, and
contact return latencies in females. Recent studies
have examined the effects of local anesthesia of the
genital organs on the female sexual response.
However, differences in methodology between
studies have led to inconclusive results. Further-
more, the role of clitoral stimulation in female rat
sexual behavior has not been well documented.
This study examined the effect of vaginocervical
anesthesia and clitoral–vaginocervical anesthesia
on sexual experience during paced sexual behavior
in female rats. Rats were surgically ovariectomized
and treated with estrogens to modulate estrous
cycles; their sexual behavior was examined under
paced mating conditions with different males to
avoid development of conditioned partner prefer-
ence. The timing of entries and exits to the males’
compartment, as well as type of stimuli received by
the male and the intensity of lordosis, were
recorded over ﬁve weekly trials. Lidocaine treat-
ment was balanced with vehicle controls that
received the same type of stimuli during drug
application; each group was compared with the
appropriate control group. Females with anesthe-
sia of the vaginocervical area had reduced contact
return latencies to intromissions that were related
to sexual experience. Females with anesthesia of
the clitoris–vaginocervical area spent signiﬁcantly
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more time with the males and returned to them
more quickly after an ejaculation compared with
the vehicle-treated controls. Local anesthesia of
the clitoris–vaginocervical area in sexually experi-
enced females did not alter any aspect of female
sexual behavior.
The authors explain that under normal paced
conditions, the female rat is attracted toward the
male through various sensory cues. Particular cues
include genital sensory input received from the
male during a mount, intromission, or ejaculation
that induce a reward signal. Under normal condi-
tions, males require several intromissions before
ejaculation can occur. The positive feedback of this
genitally evoked reward strengthens the approach
behavior by the female to allow subsequent mating
interactions to occur; this sets the stage for the
male to be able to ejaculate. Females withdraw
from the males for a short time after genital stimu-
lation because the stimuli they receive is tempo-
rarily aversive.
These data suggest that anesthesia of the clitoris
area reduces the intensity of the sensory input for
the female rat after an ejaculation during copula-
tion. No signiﬁcant changes in contact return
latencies were seen with anesthesia of the
vaginocervical area alone. Paced mating behavior
in sexually experienced females did not a change
with a single application of lidocaine to the
clitoral–vaginocervical area. Taken together, the
authors conclude that the complex pattern of
female-paced behavior emerges with sexual expe-
rience and that the sensory information received
during these sessions modulates the behavioral
patterns that emerge.
Lesley Marson, PhD
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